[ Investors » Press Releases ]
2008 | 2007 | 2006 | 2005 | 2004
Press Releases
|
PolyMedix Appoints Vice President of Drug Development |
|
November 9, 2005
Timothy Henkel, M.D., Ph.D., Appointed Vice President Drug Development and
Chief Medical Officer
PolyMedix, Inc. announced today that it has appointed Dr. Timothy Henkel as Vice President, Drug Development and Chief Medical Officer.
Dr. Timothy Henkel, M.D., Ph.D., has joined PolyMedix as Vice President of Drug Development and Chief Medical Officer. Dr. Henkel has developed a number of antibiotic and antifungal drugs. He comes to PolyMedix from Vicuron Pharmaceuticals, where from 2001 to 2005 he was Executive Vice President and Chief Medical Officer.
Read More |
|
PolyMedix Closes $6 Million Series B Financing |
|
January 3, 2005
PolyMedix, Inc. announced today that it has closed a $6 million Series B equity financing, raising $4 million in a second closing.
These funds will be used to complete the preclinical development of the Company's lead antibiotic compound, for which an IND and initiation of human clinical trials are planned for later this year. PolyMedix also plans to seek a Series C financing later this year, the proceeds of which will be used to fund clinical development if its antibiotic drug compounds.
Read More |
Press releases contain forward-looking statements that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," “hopes,” "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forwardlooking
statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
return to top ^ |
